EU court upholds EUR 13.96 mn fine on Unichem Lab in Perindopril litigation

Image
Press Trust of India New Delhi
Last Updated : Dec 13 2018 | 12:35 PM IST

Drug firm Unichem Laboratories Thursday said a Europe court has upheld the decision to impose a fine of EUR 13.96 million (approx Rs 113.50 crore) on the company and its subsidiary by the European Commission (EC) in a litigation over blood pressure lowering drug Perindopril.

"General Court of the European Union has on December 12, 2018, rejected the appeals... and has confirmed the fine of EUR 13.96 million," Unichem Laboratories said in a regulatory filing.

The company said "it is disappointed and is currently reviewing the detailed judgment. It will take appropriate legal advice on further action, including the possibility of filing of an appeal before the Court of Justice of the European Union".

In 2014, Lupin and Unichem Laboratories were among six global drug makers on which the the European Commission had imposed a collective fine of EUR 427.7 million for striking deals to prevent entry of cheaper version of blood pressure drug Perindopril in the EU.

European Commission had imposed a fine of EUR 13.96 million on Unichem Laboratories and its subsidiary.

Niche Generics and Unichem then appealed the decision of the European Commission before the General Court of the European Union on September 22, 2014.

Niche is a wholly-owned subsidiary of Unichem Laboratories.

The court also upheld a fine of EUR 40 million (over Rs 325 crore) on Lupin.

Shares of Unichem Laboratories were trading 0.55 per cent lower at Rs 191.60 apiece on BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 13 2018 | 12:35 PM IST

Next Story